C4 Therapeutics, Inc. (Nasdaq: CCCC) announced it will present new biomarker data on the immunomodulatory effects of cemsidomide in combination ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE